Journal of ethnopharmacology · 2025
An investigation into the efficacy and mechanism of Berchemia kulingensis leaves in suppressing synovial tissue inflammation in a rat model of gouty arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiong Youyi, Xu Haonan, Zhang Yiming, Chen Zixiang, Wei Fang, Yu Lulu, Zhang Beibei, Guo Zhenchao, Li Xianqiang, Dou Jinfeng, Yang Changshui
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: The pharmacological activities of Berchemia kulingensis (BK) leaves, traditionally used as a tea for joint discomfort relief in Chinese folk, remain unexplored.
AIM OF THE STUDY: To explore the potential therapeutic effects of BK-leaves on gouty arthritis (GA), thus providing a scientific basis for their folk use and pharmaceutical development.
MATERIALS AND METHODS: The secondary metabolites of BK-leaves were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology. Combined with activity prediction, the therapeutic potential and related mechanisms of action were further systematically explored through GA rat models and in vitro cell models.
RESULTS: The prediction of the identified compounds' biological activity suggests BK leaves may have potential therapeutic effects on GA. Animal experiments show that extract of BK-leaves alleviated synovial inflammation in rats, reduced the concentrations of tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), IL-6, IL-8, cyclooxygenase (COX)-2, and matrix metalloproteinase (MMP)-9, inhibited protein expression of NLR family pyrin domain-containing protein 3 (NLRP3) and Toll-like receptor 4 (TLR4), as well as phosphorylation of proteins including p65 subunit of nuclear factor (NF)-κB, NF-κB inhibitor kinase (IKK) alpha/beta, and signal transducer and activator of transcription 3 (STAT3), while simultaneously upregulated protein expression of the nuclear factor κB inhibitor alpha (IκBα) (P < 0.05, P < 0.01, or P < 0.001). Additionally, BK-leaf extract inhibited xanthine oxidase (XO) activity in vitro (P < 0.05, 0.01, or 0.001).
CONCLUSION: BK-leaf has potential therapeutic value for GA, and its mechanism may be related to regulating the TLR4-NF-κB signaling pathway and inhibiting XO activity.
AIM OF THE STUDY: To explore the potential therapeutic effects of BK-leaves on gouty arthritis (GA), thus providing a scientific basis for their folk use and pharmaceutical development.
MATERIALS AND METHODS: The secondary metabolites of BK-leaves were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology. Combined with activity prediction, the therapeutic potential and related mechanisms of action were further systematically explored through GA rat models and in vitro cell models.
RESULTS: The prediction of the identified compounds' biological activity suggests BK leaves may have potential therapeutic effects on GA. Animal experiments show that extract of BK-leaves alleviated synovial inflammation in rats, reduced the concentrations of tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), IL-6, IL-8, cyclooxygenase (COX)-2, and matrix metalloproteinase (MMP)-9, inhibited protein expression of NLR family pyrin domain-containing protein 3 (NLRP3) and Toll-like receptor 4 (TLR4), as well as phosphorylation of proteins including p65 subunit of nuclear factor (NF)-κB, NF-κB inhibitor kinase (IKK) alpha/beta, and signal transducer and activator of transcription 3 (STAT3), while simultaneously upregulated protein expression of the nuclear factor κB inhibitor alpha (IκBα) (P < 0.05, P < 0.01, or P < 0.001). Additionally, BK-leaf extract inhibited xanthine oxidase (XO) activity in vitro (P < 0.05, 0.01, or 0.001).
CONCLUSION: BK-leaf has potential therapeutic value for GA, and its mechanism may be related to regulating the TLR4-NF-κB signaling pathway and inhibiting XO activity.